×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
FOLD – amicus therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
FOLD
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
1/9
07:03 pm
fold
Assessing Amicus Therapeutics (FOLD) Valuation After Recent Share Price Momentum [Yahoo! Finance]
Low
Report
Assessing Amicus Therapeutics (FOLD) Valuation After Recent Share Price Momentum [Yahoo! Finance]
1/9
04:31 am
fold
Is Amicus Therapeutics (FOLD) Pricing Reflect Recent 45% Surge And DCF Upside Potential [Yahoo! Finance]
Low
Report
Is Amicus Therapeutics (FOLD) Pricing Reflect Recent 45% Surge And DCF Upside Potential [Yahoo! Finance]
1/8
12:49 pm
fold
Halper Sadeh LLC Encourages THS, FOLD, REVG Shareholders to Contact the Firm to Discuss Their Rights
Low
Report
Halper Sadeh LLC Encourages THS, FOLD, REVG Shareholders to Contact the Firm to Discuss Their Rights
1/6
07:25 am
fold
Amicus Therapeutics (NASDAQ:FOLD) was downgraded by analysts at Guggenheim from a "strong-buy" rating to a "hold" rating.
Low
Report
Amicus Therapeutics (NASDAQ:FOLD) was downgraded by analysts at Guggenheim from a "strong-buy" rating to a "hold" rating.
12/29
08:00 am
fold
Amicus Therapeutics (NASDAQ:FOLD) was downgraded by analysts at Leerink Partners from an "outperform" rating to a "market perform" rating. They now have a $14.50 price target on the stock.
Low
Report
Amicus Therapeutics (NASDAQ:FOLD) was downgraded by analysts at Leerink Partners from an "outperform" rating to a "market perform" rating. They now have a $14.50 price target on the stock.
12/26
03:28 pm
fold
Amicus Therapeutics Investment Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Amicus Therapeutics, Inc. - FOLD
Low
Report
Amicus Therapeutics Investment Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Amicus Therapeutics, Inc. - FOLD
12/24
10:32 pm
fold
Assessing Amicus Therapeutics (FOLD) Valuation After Its Recent Share Price Rally [Yahoo! Finance]
Neutral
Report
Assessing Amicus Therapeutics (FOLD) Valuation After Its Recent Share Price Rally [Yahoo! Finance]
12/23
02:53 pm
fold
BioMarin Pharmaceutical (BMRN) Stock Is Up, What You Need To Know [Yahoo! Finance]
Neutral
Report
BioMarin Pharmaceutical (BMRN) Stock Is Up, What You Need To Know [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
11/4/2025
07:00 am
fold
amicus therapeutics, inc.
BEAT
Report
-1.2%
amicus therapeutics, inc.
7/31/2025
07:00 am
fold
amicus therapeutics, inc.
BEAT
Report
-6.4%
amicus therapeutics, inc.
2/19/2025
07:00 am
fold
amicus therapeutics, inc.
BEAT
Report
-4.3%
amicus therapeutics, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
1/6
07:48 pm
fold
Form 4 AMICUS THERAPEUTICS, For: Jan 02 Filed by: Rosenberg Ellen
Low
Report
Form 4 AMICUS THERAPEUTICS, For: Jan 02 Filed by: Rosenberg Ellen
1/6
07:47 pm
fold
Form 4 AMICUS THERAPEUTICS, For: Jan 02 Filed by: Castelli Jeff
Low
Report
Form 4 AMICUS THERAPEUTICS, For: Jan 02 Filed by: Castelli Jeff
1/6
07:46 pm
fold
Form 4 AMICUS THERAPEUTICS, For: Jan 02 Filed by: Prout Samantha
Low
Report
Form 4 AMICUS THERAPEUTICS, For: Jan 02 Filed by: Prout Samantha
1/6
07:45 pm
fold
Form 4 AMICUS THERAPEUTICS, For: Jan 02 Filed by: Clark David Michael
Low
Report
Form 4 AMICUS THERAPEUTICS, For: Jan 02 Filed by: Clark David Michael
12/30
06:05 pm
fold
Form 4 AMICUS THERAPEUTICS, For: Dec 26 Filed by: Harford Simon N.R.
Low
Report
Form 4 AMICUS THERAPEUTICS, For: Dec 26 Filed by: Harford Simon N.R.
12/30
06:05 pm
fold
Form 4 AMICUS THERAPEUTICS, For: Dec 26 Filed by: Campbell Bradley L
Low
Report
Form 4 AMICUS THERAPEUTICS, For: Dec 26 Filed by: Campbell Bradley L
12/23
04:16 pm
fold
Form 4 AMICUS THERAPEUTICS, For: Dec 19 Filed by: Clark David Michael
Low
Report
Form 4 AMICUS THERAPEUTICS, For: Dec 19 Filed by: Clark David Michael
12/19
04:23 pm
fold
Form 144 AMICUS THERAPEUTICS, Filed by: Clark David Michael
Low
Report
Form 144 AMICUS THERAPEUTICS, Filed by: Clark David Michael
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
4/2
Amicus Therapeutics, Inc. (NASDAQ: FOLD) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating.
8.5%
2/4 Amicus Therapeutics, Inc. (NASDAQ: FOLD) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $20.00 price target on the stock, up previously from $19.00. 7.0%
3/9 Form 4 AMICUS THERAPEUTICS, For: Mar 05 Filed by: Campbell Bradley L 6.9%
2/4 Form 4 AMICUS THERAPEUTICS, For: Jan 31 Filed by: Crowley John F 6.5%
6/17 Amicus Therapeutics, Inc. (NASDAQ: FOLD) is now covered by analysts at HC Wainwright. They set a "buy" rating on the stock. 5.8%
1/14 Form 4 AMICUS THERAPEUTICS, For: Jan 10 Filed by: Barth Jay 5.4%
10/3 Is Amicus Therapeutics, Inc. (NASDAQ:FOLD) A Volatile Stock? [Yahoo! Finance News] 4.8%
3/24 Form 4 AMICUS THERAPEUTICS, For: Mar 20 Filed by: Crowley John F 4.4%
7/17 Amicus Therapeutics, Inc. (NASDAQ: FOLD) was given a new $18.00 price target on by analysts at HC Wainwright. They now have a "buy" rating on the stock. 4.4%
4/24 Amicus Therapeutics to Announce First Quarter 2020 Financial Results on May 7, 2020 4.3%
2/4 Amicus Therapeutics, Inc. (NASDAQ: FOLD) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $20.00 price target on the stock, up previously from $19.00. 7.0%
3/9 Form 4 AMICUS THERAPEUTICS, For: Mar 05 Filed by: Campbell Bradley L 6.9%
2/4 Form 4 AMICUS THERAPEUTICS, For: Jan 31 Filed by: Crowley John F 6.5%
6/17 Amicus Therapeutics, Inc. (NASDAQ: FOLD) is now covered by analysts at HC Wainwright. They set a "buy" rating on the stock. 5.8%
1/14 Form 4 AMICUS THERAPEUTICS, For: Jan 10 Filed by: Barth Jay 5.4%
10/3 Is Amicus Therapeutics, Inc. (NASDAQ:FOLD) A Volatile Stock? [Yahoo! Finance News] 4.8%
3/24 Form 4 AMICUS THERAPEUTICS, For: Mar 20 Filed by: Crowley John F 4.4%
7/17 Amicus Therapeutics, Inc. (NASDAQ: FOLD) was given a new $18.00 price target on by analysts at HC Wainwright. They now have a "buy" rating on the stock. 4.4%
4/24 Amicus Therapeutics to Announce First Quarter 2020 Financial Results on May 7, 2020 4.3%
TOP News Decliners
10/3
Amicus snaps back on positive data from Pompe Disease study of AT-GAA [Seeking Alpha]
-10.0%
8/2 Amicus Therapeutics Receives Marketing Authorization for Galafold® (migalastat) for Fabry Disease in Argentina -9.0%
3/2 Amicus Therapeutics Announces Full-Year 2019 Financial Results and 2020 Corporate Updates -8.4%
8/8 Amicus Therapeutics, Inc. (FOLD) CEO John Crowley on Q2 2019 Results - Earnings Call Transcript [Seeking Alpha] -7.5%
5/29 Amicus Therapeutics Announces Public Offering of Common Stock -7.2%
12/4 Form 4 AMICUS THERAPEUTICS, For: Dec 02 Filed by: Crowley John F -6.8%
8/8 Q2/2019 6/30/2019 EPS -0.360 ZacksConsensus -0.340 ActVsEst (0.020) - Miss -6.7%
7/4 Why Amicus Therapeutics' Stock Perked Up in June [The Motley Fool] -6.2%
1/18 Amicus Therapeutics, Inc. (NASDAQ: FOLD) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. -6.0%
1/13 Form 8-K AMICUS THERAPEUTICS, For: Jan 13 -5.7%
8/2 Amicus Therapeutics Receives Marketing Authorization for Galafold® (migalastat) for Fabry Disease in Argentina -9.0%
3/2 Amicus Therapeutics Announces Full-Year 2019 Financial Results and 2020 Corporate Updates -8.4%
8/8 Amicus Therapeutics, Inc. (FOLD) CEO John Crowley on Q2 2019 Results - Earnings Call Transcript [Seeking Alpha] -7.5%
5/29 Amicus Therapeutics Announces Public Offering of Common Stock -7.2%
12/4 Form 4 AMICUS THERAPEUTICS, For: Dec 02 Filed by: Crowley John F -6.8%
8/8 Q2/2019 6/30/2019 EPS -0.360 ZacksConsensus -0.340 ActVsEst (0.020) - Miss -6.7%
7/4 Why Amicus Therapeutics' Stock Perked Up in June [The Motley Fool] -6.2%
1/18 Amicus Therapeutics, Inc. (NASDAQ: FOLD) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. -6.0%
1/13 Form 8-K AMICUS THERAPEUTICS, For: Jan 13 -5.7%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: